Use of the Pay-for-Performance Program in Reducing Sarcopenia Risk: A Nested Case-Control Study Among Patients with...

Area of Science:

• Endocrinology
• Geriatrics
• Public Health

Background:

• Type 2 diabetes mellitus (T2DM) management has advanced, yet sarcopenia remains a significant complication.
• Pay-for-performance (P4P) is a quality improvement strategy with limited research on its impact on sarcopenia prevention.
• Sarcopenia poses a growing global healthcare challenge, particularly in diabetic populations.

Purpose of the Study:

• To investigate the association between participation in P4P programs and the risk of developing sarcopenia among T2DM patients.
• To evaluate the impact of P4P on sarcopenia prevention within a large cohort of individuals with T2DM.

Main Methods:

• A nested case-control study utilized a large Taiwanese claims dataset (2001-2013).
• Individuals aged 20-70 with newly diagnosed T2DM were followed for sarcopenia occurrence.
• Conditional logistic regression analysis was employed to determine the adjusted odds ratio (aOR) for sarcopenia risk associated with P4P participation.

Main Results:

• The study included 3475 sarcopenia cases and 6948 matched controls.
• P4P program participants exhibited a significantly lower risk of sarcopenia (aOR = 0.66; 95% CI: 0.61-0.74).
• Earlier enrollment (within 1 year of T2DM diagnosis) and higher intensity P4P participation correlated with greater risk reduction.

Conclusions:

• Integrating P4P into standard T2DM care may be an effective strategy for sarcopenia prevention.
• The findings underscore the potential benefits of interdisciplinary collaboration and timely implementation of P4P programs.
• P4P demonstrates promise in mitigating a key complication of type 2 diabetes mellitus.